Revolutionizing Immuno-Oncology
Discover our innovative approach to immunotherapy and how it's changing the game in cancer treatment.
Opportunities in Immunotherapy
The POP BIO SNAP platform has the potential serve as a powerful platform for the development of immunotherapies.
A New Approach for Short Peptide Cancer Vaccines
SNAP liposomes contain synthetic MPLA, QS-21 and Cobalt porphyrin phospholipid (CoPoP)
CoPoP enables liposomes to stably bind short MHC-I epitopes upon admixture.
Better delivery of epitopes and adjuvants to immune cells in draining lymph nodes
Induce higher frequency of antigen specific CD8+ T cells with > 10,000X lower peptide dosing
Instantly Harness the Power of Particle-Based Vaccines
Enhancing Antigen Display and Immune Response with SNAP Liposomes
SNAP liposomes contain Cobalt porphyrin phospholipid (CoPoP) and the lipid adjuvants synthetic MPLA and optionally QS-21
CoPoP enables rapid and biostable display of antigens on liposomes with simple mixing.
SNAP focuses the immune response on antigen of interest with protein-free scaffold technology
Our Clinical Pipeline
At POP Biotechnologies, we are leading the way in developing innovative immunotherapies. Our active Clinical Pipeline includes EuCorVac-19, our first vaccine currently in Phase III Trials. With our groundbreaking approach, we aim to revolutionize cancer treatment and improve patient outcomes.
Selected Publications
Below is our carefully curated shortlist of more than 20 peer-reviewed publications that have been rigorously vetted by experts in the field and deemed to be of the highest quality.